Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
USD 4.92
(1.76%)
USD 4.92
(1.76%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 28.27 Million USD | -57.36% |
| 2022 | 66.31 Million USD | -38.45% |
| 2021 | 107.73 Million USD | 5.31% |
| 2020 | 102.29 Million USD | 108.16% |
| 2019 | 49.14 Million USD | 4.58% |
| 2018 | 46.98 Million USD | -29.84% |
| 2017 | 66.97 Million USD | 274.43% |
| 2016 | 17.88 Million USD | 38.93% |
| 2015 | 12.87 Million USD | 95.06% |
| 2014 | 6.6 Million USD | 2060.5% |
| 2013 | 305.52 Thousand USD | 55960.46% |
| 2012 | 544.98 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 151.97 Million USD | 20.86% |
| 2024 Q1 | 125.74 Million USD | 344.76% |
| 2023 Q1 | 51.64 Million USD | -22.12% |
| 2023 FY | 28.27 Million USD | -57.36% |
| 2023 Q4 | 28.27 Million USD | -22.08% |
| 2023 Q3 | 36.28 Million USD | -17.02% |
| 2023 Q2 | 43.72 Million USD | -15.34% |
| 2022 Q4 | 66.31 Million USD | -10.18% |
| 2022 Q3 | 73.83 Million USD | -10.04% |
| 2022 Q2 | 82.06 Million USD | -14.22% |
| 2022 Q1 | 95.67 Million USD | -11.19% |
| 2022 FY | 66.31 Million USD | -38.45% |
| 2021 FY | 107.73 Million USD | 5.31% |
| 2021 Q1 | 140.14 Million USD | 37.0% |
| 2021 Q3 | 119.57 Million USD | -0.86% |
| 2021 Q2 | 120.6 Million USD | -13.94% |
| 2021 Q4 | 107.73 Million USD | -9.9% |
| 2020 Q3 | 95.83 Million USD | -2.32% |
| 2020 Q1 | 65.2 Million USD | 32.68% |
| 2020 Q4 | 102.29 Million USD | 6.74% |
| 2020 FY | 102.29 Million USD | 108.16% |
| 2020 Q2 | 98.11 Million USD | 50.48% |
| 2019 FY | 49.14 Million USD | 4.58% |
| 2019 Q4 | 49.14 Million USD | -27.87% |
| 2019 Q3 | 68.13 Million USD | -19.01% |
| 2019 Q2 | 84.12 Million USD | -17.03% |
| 2019 Q1 | 101.39 Million USD | 115.78% |
| 2018 Q4 | 46.98 Million USD | -23.2% |
| 2018 Q3 | 61.18 Million USD | -12.96% |
| 2018 Q2 | 70.28 Million USD | -8.88% |
| 2018 Q1 | 77.13 Million USD | 15.17% |
| 2018 FY | 46.98 Million USD | -29.84% |
| 2017 FY | 66.97 Million USD | 274.43% |
| 2017 Q4 | 66.97 Million USD | 74.33% |
| 2017 Q1 | 50.6 Million USD | 182.91% |
| 2017 Q3 | 38.41 Million USD | -13.78% |
| 2017 Q2 | 44.56 Million USD | -11.95% |
| 2016 FY | 17.88 Million USD | 38.93% |
| 2016 Q2 | 22.62 Million USD | 115.6% |
| 2016 Q1 | 10.49 Million USD | -18.49% |
| 2016 Q4 | 17.88 Million USD | -9.46% |
| 2016 Q3 | 19.75 Million USD | -12.69% |
| 2015 Q2 | 9.56 Million USD | 82.31% |
| 2015 Q1 | 5.24 Million USD | -20.52% |
| 2015 Q4 | 12.87 Million USD | -3.44% |
| 2015 FY | 12.87 Million USD | 95.06% |
| 2015 Q3 | 13.33 Million USD | 39.41% |
| 2014 Q4 | 6.6 Million USD | -13.48% |
| 2014 Q2 | 8.53 Million USD | 4316.91% |
| 2014 Q1 | 193.22 Thousand USD | -36.75% |
| 2014 FY | 6.6 Million USD | 2060.5% |
| 2014 Q3 | 7.62 Million USD | -10.61% |
| 2013 FY | 305.52 Thousand USD | 55960.46% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 305.52 Thousand USD | 0.0% |
| 2012 FY | 544.98 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 96.601% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 96.983% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 96.365% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 82.917% |
| bluebird bio, Inc. | 619.16 Million USD | 95.434% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 77.534% |
| Imunon, Inc. | 21.91 Million USD | -28.991% |
| Editas Medicine, Inc. | 499.15 Million USD | 94.336% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.894% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 99.157% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 97.641% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 99.13% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 97.993% |
| Verastem, Inc. | 149.71 Million USD | 81.116% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.965% |
| Waters Corporation | 4.62 Billion USD | 99.389% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.971% |
| Biogen Inc. | 26.84 Billion USD | 99.895% |
| Nektar Therapeutics | 398.03 Million USD | 92.897% |
| Perrigo Company plc | 10.8 Billion USD | 99.738% |
| Dynavax Technologies Corporation | 997.09 Million USD | 97.165% |
| Illumina, Inc. | 10.11 Billion USD | 99.72% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 96.377% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 87.294% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 56.961% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.587% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 82.898% |
| Evolus, Inc. | 188.99 Million USD | 85.041% |
| Adicet Bio, Inc. | 207.29 Million USD | 86.361% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 85.678% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.915% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 86.262% |
| FibroGen, Inc. | 423.52 Million USD | 93.325% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 99.737% |
| OPKO Health, Inc. | 2.01 Billion USD | 98.595% |
| Homology Medicines, Inc. | 47.05 Million USD | 39.919% |
| Geron Corporation | 394.07 Million USD | 92.826% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 99.262% |
| Exelixis, Inc. | 2.94 Billion USD | 99.039% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 92.328% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 81.687% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 97.827% |
| Zoetis Inc. | 14.28 Billion USD | 99.802% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 95.194% |
| Abeona Therapeutics Inc. | 64 Million USD | 55.826% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.876% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 49.468% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 99.054% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 99.134% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 95.451% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 98.369% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 97.305% |
| Insmed Incorporated | 1.32 Billion USD | 97.874% |
| TG Therapeutics, Inc. | 329.58 Million USD | 91.422% |
| Incyte Corporation | 6.78 Billion USD | 99.583% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 98.459% |